Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Sanofi-Aventis Stories

2012-04-19 02:29:54

PARIS, April 19, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor - phosphodiesterase type 4 inhibitor - in patients with Parkinson's disease (PD). (Logo: http://photos.prnewswire.com/prnh/20120419/NY89994LOGO ) (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)...

2012-04-14 23:04:21

Parker Waichman LLP is Already Representing Dozens of Plaintiffs in Plavix Gastrointestinal and Cerebral Bleeding Side Effect Lawsuits New York, NY (PRWEB) April 13, 2012 Parker Waichman LLP, a national law firm representing people injured by defective drugs, is investigating lawsuit claims on behalf of people who allegedly suffered severe bleeding side effects as a result of Plavix, a blood thinner made by Bristol -Myers Squibb Company and Sanofi-Aventis U.S., L.L.C. Parker Waichman LLP...

2012-04-04 18:20:13

PARIS and TARRYTOWN, N.Y., April 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP® (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer...

2012-03-29 22:16:07

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal. The article Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial, reports on the use of a simple cheek swab test, the Spartan RX CYP2C19,...

2012-03-29 02:26:23

Introducing STARsystem(TM) - a revolutionary web-based platform providing support for people with diabetes to self-manage LAVAL, QC, March 29, 2012 /PRNewswire/ - Diabetes management is entering a new era with the Sanofi STARsystem( TM) support platform and the new first-of-its-kind iBGStar( TM) meter.  Now, with STARsystem( TM), at any time of day people living with diabetes can access personalized education, an action plan to help optimize their health, health coaching and much...

2012-03-27 10:23:45

LAVAL, QC, March 27, 2012 /PRNewswire/ - Join us to celebrate the Canadian debut of STARsystem a revolutionary diabetes management system by Sanofi connected to a team of personal health coaches. In addition to learning about five areas that improve wellness (monitoring, managing, eating, moving and feeling), you will be among the first in Canada to test out iBGStar the first blood glucose meter that connects to an iPhone or iPod touch! When: Thursday, March...

2012-03-19 02:24:57

CAMBRIDGE, Mass., March 19, 2012 /PRNewswire/ -- ImmusanT announced today that Patrick H. Griffin, MD, has joined the biopharmaceutical company as Chief Medical Officer and Senior Vice President of Development, and Michelle Hipwood joins as Director of Finance and Operations. "Patrick brings to ImmusanT exceptional expertise as a gastroenterologist, drug developer and evaluator of numerous drug candidates for immune and inflammatory diseases. The addition of Patrick is pivotal as we...

2012-03-16 08:50:41

PARIS, March 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts. The acquisition is subject to customary closing conditions. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Pluromed has developed a proprietary polymer technology, called Rapid Transition...

2012-03-01 15:05:00

CAMBRIDGE, Mass., March 1, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has elected Thomas R. Hodgson, a current member and Lead Director of Idenix's Board and former President and Chief Operating Officer of Abbott Laboratories, to serve as Chairman of the Board. Additionally, Idenix has appointed Michael S. Wyzga to its Board of...

2012-02-23 07:00:00

BRIDGEWATER, N.J., Feb. 23, 2012 /PRNewswire/ -- Sanofi US announced today that it is accepting entries for the Data Design Diabetes(TM) Innovation Challenge. The Innovation Challenge is aligned with the United States government's initiative to use an open dialogue to drive action toward a three-part aim: innovation in the quality, delivery and cost of diabetes care. The kickoff earlier this year crowd-sourced answers to the question, "What matters most to you?" as it relates to diabetes, and...